Updates are available Correction dated 2026-07-17
Click to view Correction: https://doi.org/10.1038/s44318-026-00862-5
-
Authors
Lai, Chun-Fui https://orcid.org/0009-0000-9967-8054
Cushing, Victoria I
Olden, Ellen https://orcid.org/0000-0001-8430-9969
Bevan, Charlotte L https://orcid.org/0000-0002-7533-0552
Coombes, R Charles https://orcid.org/0000-0002-4811-1100
Greber, Basil J https://orcid.org/0000-0001-9379-7159
Buluwela, Laki https://orcid.org/0000-0001-6973-334X
Ali, Simak https://orcid.org/0000-0002-1320-0816
-
Funding
Funding for this research was provided by:
Prostate Cancer UK (RIA19-ST2-004)
UKRI | Medical Research Council (MR/V009354/1)
UKRI | Medical Research Council (MR/R015732/1)
- License Information
-
More Information
Article History
Received: 17 December 2024
Revised: 28 July 2025
Accepted: 13 August 2025
First Online: 8 September 2025
Disclosure and competing interests statement
: SA and RCC are named inventors on patents concerning CDK7 inhibitors, which have been licensed to Carrick Therapeutics, own shares in and has received royalties from Carrick Therapeutics. RCC is on the advisory board for Carrick Therapeutics. SA, LB and CLB have also received research funding from Carrick Therapeutics. EO was funded by a PhD programme with funding from Carrick Therapeutics.
